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1  | INTRODUC TION
Transplantation has become an established treatment for end-stage 
organ diseases and is a highly regulated field. There are several 
threats to transplantation but one particularly important threat is that 
of an emerging infectious disease. Since the 1980s, there have been 
several emerging viral diseases including HIV in the late 1980s/early 
1990s, SARS-CoV, West Nile Virus, pandemic influenza A/H1N1, 
Zika, Ebola, and now pandemic COVID-19 caused by SARS-CoV-2. 
For each of these threats, transplant programs have responded in 
a coordinated fashion by assessing the risk of donor transmission, 
assessing the severity of disease in the recipient, and recognizing the 
potential for transmission to health-care workers.1-5 This knowledge 
has then been used to generate algorithms for donor screening, not 
using organs from potentially infected donors, and recipient man-
agement. Many of these emerging viruses have been manageable, 
sometimes only limited to certain geographic areas, and transplan-
tation/donation has been able to adapt and continue to provide 
this life-saving therapy in a safe and effective manner. The current 
COVID-19 pandemic is unique and unprecedented in modern times. 
It has crossed borders and infected >180 000 persons worldwide 
that we know of, with likely many more undiagnosed cases. It has 
been difficult to contain partly due to the contagious nature of the 
virus and mild illness in a majority of individuals. Nevertheless, the 
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The COVID-19 pandemic has rapidly evolved and changed our way of life in an un-
precedented manner. The emergence of COVID-19 has impacted transplantation 
worldwide. The impact has not been just restricted to issues pertaining to donors or 
recipients, but also health-care resource utilization as the intensity of cases in certain 
jurisdictions exceeds available capacity. Here we provide a personal viewpoint rep-
resenting different jurisdictions from around the world in order to outline the impact 
of the current COVID-19 pandemic on organ transplantation. Based on our collective 
experience, we discuss mitigation strategies such as donor screening, resource plan-
ning, and a staged approach to transplant volume considerations as local resource is-
sues demand. We also discuss issues related to transplant-related research during the 
pandemic, the role of transplant infectious diseases, and the influence of transplant 
societies for education and disseminating current information.
K E Y W O R D S
clinical decision-making, clinical research/practice, donors and donation: donor-derived 
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emergence of COVID-19 has impacted transplantation worldwide. 
The impact has not been just restricted to issues around donors or 
recipients, but also health-care resource utilization as the intensity 
of cases in certain jurisdictions exceeds available capacity. Based on 
our collective experience, we suggest mitigation strategies such as 
donor screening approaches, resource planning, and a staged ap-
proach to transplant volume considerations as local resource issues 
demand. We also discuss issues related to the management of im-
munosuppression trials during the pandemic, and the role of trans-
plant infectious diseases and transplant societies for education and 
disseminating current information. We believe our collective experi-
ence will be valuable to the transplant community in the absence of 
hard published research findings this early in the pandemic.
2  | APPROACH TO DONATION
There is a potential for COVID-19 to be transmitted by organ do-
nation although the risk of this is unclear and we are not aware of 
any reports of transmission. The virus is primarily isolated from the 
respiratory tract suggesting the lung is a very high-risk for trans-
mission when used from an infected donor. However, virus is also 
been reported to be isolated from the blood in up to 15% of cases 
and therefore, all organs may be at risk of acquisition.6 With the 
SARS epidemic of 2003, autopsy data demonstrated virus in almost 
all organs including the liver, kidney, and intestines.7 Donor screen-
ing from both a clinical and laboratory perspective is therefore an 
important consideration and has been the subject of much discus-
sion.8 In areas with significant community transmission, if organ 
donation is to proceed in a safe manner, the authors recommend 
that both clinical and rapid laboratory screening is required. This 
approach to donation may differ in countries depending on the de-
gree of community-transmission of COVID-19. However, many areas 
have noted that due to limitations in test availability the true rate 
of community penetration may be unknown. During the SARS-CoV 
outbreak of 2003 in Toronto, a clinical donor screening tool was in-
stituted, incorporating epidemiological and clinical features of the 
donor, which then allowed deceased-donor transplantation to con-
tinue.2 However, unlike in 2003, there has been rapid development 
of nucleic acid testing (NAT) for SARS-CoV-2 and therefore, testing 
of nasopharyngeal specimens has been incorporated and is the cor-
nerstone of donor screening algorithms in several jurisdictions. Real-
time NP swab donor screening has been successfully deployed in 
organ procurement organizations (OPOs) within Canada, Italy, Spain, 
and South Korea. However, many questions remain, including the 
false negative rates of testing which can be due to inappropriate col-
lection or a patient early in the incubation period. Since SARS-CoV-2 
is known to use the ACE2 receptor for viral entry, a bronchoalveo-
lar lavage (BAL) specimen may be more appropriate than naso/oro-
pharyngeal swab. However, bronchoscopy would have the potential 
risk of aerosolization and may not be logistically feasible. For this 
approach to be successful, the test result must also be rapidly avail-
able. Laboratory-developed or commercial NAT testing needs to be 
made available to OPOs with results in hours. Ruling out COVID-
19 in a donor is also essential for the safety of organ procurement 
teams. Shortages of testing kits, reagents, and laboratory resources 
to carry out donor screening in the midst of a pandemic are also a 
major consideration.
In Canada, we developed a COVID-19 donor clinical screen-
ing tool and also started NP swab NAT screening for COVID-19 
(Figure 1). For areas with significant community transmission, the 
tool could be modified to reduce the importance of travel history. 
In the latter case, NAT testing would play a much larger role but the 
tool allows a second layer of redundancy in the screening process. 
Collectively the authors have had experience with asymptomatic 
NAT positive donors.
In Switzerland, where virus is currently widely circulating in the 
community, we established universal screening for all deceased do-
nors by NAT in NP swab or BAL on March 5, 2020 (Table 1). Given 
the potential increase in risk for health personnel and current lim-
ited resources in the ICU for performing bronchoscopy, we favor NP 
swab over BAL for screening of SARS-CoV-2. Of note, given the wide 
clinical presentation of COVID-19, potential donors can be asymp-
tomatic or mildly symptomatic at the time of donation, thus high-
lighting the need for universal screening.
In Italy, where there is significant community transmission, de-
ceased donor screening with NAT for SARS-CoV-2 on BAL has be-
come mandatory starting from February 23, 2020. At the time of this 
manuscript none of the screened donors has been found positive. 
The main problem in Italy is the huge number of patients requiring 
mechanical ventilation and that many ICUs that have been trans-
formed to COVID-19 ICUs. For this reason, the number of potential 
donors is expected to significantly decrease.
In Spain, with high community transmission, universal screening 
(through at least one NP specimen and, if feasible, one lower respira-
tory tract sample) is now mandatory for all lung and small bowel do-
nors across the country. In addition, NAT screening is also required 
for any deceased donor with recent travel to or stay in selected high-
risk Spanish regions, contact with a confirmed COVID-19 case, with 
a positive symptom screen. No donor-derived transmission has been 
reported to date.
The Japan Society for Transplantation (JST) published their for-
mal statement on March 6, 2020 (http://www.asas.or.jp/jst/pdf/
info_20200 306.pdf) and recommended to clinically screen donors for 
significant exposure to COVID-19, travel history to high-risk countries, 
and symptoms including fever and respiratory symptoms. However, due 
to limited testing capacity, universal screening has not been adopted. 
Uniquely, JST recommended for both lung and liver living donors to 
stay at home or in hospital 14 days prior to avoid COVID-19 exposure, 
in cases where transplantation can be postponed for 14 days.
The Korean Society for Transplantation (KST) released their 
recommendation on March 13, 2020. The KST recommended that 
both living and deceased donors should be tested for SARS-CoV-2 
NAT from NP swab prior to procurement. If the living donor and/
or recipient visited the highly epidemic domestic regions (Daegu 
city or Gyeongsangbuk-do Province), or had any exposure, the 
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transplant operation should be postponed for 14 days with close clin-
ical monitoring.
3  | APPROACH TO TR ANSPL ANTATION
In the face of a pandemic that may impact transplant recipients ad-
versely, decisions to continue or cease transplantation need to be 
made by programs. Although donor transmission is an ominous pos-
sibility, many of these decisions are actually independent of donor 
transmission and have to do with the following considerations: 
(1) introducing immunosuppression into patients in the midst of a 
pandemic, (2) the risk vs benefit ratio of postponing transplant vs 
proceeding, and (3) rationing of healthcare resources including both 
inpatient and outpatient resources. Lack of ventilator capacity is 
also an extremely important consideration once widespread activity 
is present. For example, kidney transplantation reduces the morbid-
ity of dialysis and is cost-saving but is not immediately life saving. 
The majority of cases of living donor kidney transplantation can be 
postponed without significant impact on the recipient. Although the 
clinical outcomes of transplant recipients with COVID-19 are not 
known, based on previous SARS and MERS publications, the mortal-
ity could be high and nasopharyngeal and tissue viral loads may be 
greater than in immune competence. Therefore, a decision must be 
made by individual programs whether to newly immunosuppress pa-
tients and send them out into the community during the COVID-19 
pandemic. The other part of the decision is how much health-care 
resource is utilized by newly transplanted patients with regard to 
readmission rates and whether during a period of strained hospital 
resources, it would be appropriate to perform kidney transplanta-
tion. It has been suggested, that the risk of infection in the commu-
nity for a newly transplanted recipient may be mitigated by either 
not using induction therapy or using an IL2 receptor antagonist for 
induction rather than polyclonal globulin induction. This is unknown 
but is a logical extension of data from other viral infections. Another 
possibility is to temporarily pause kidney transplantation but con-
tinue to transplant highly sensitized patients. This has been done in 
some jurisdictions.
F I G U R E  1   COVID-19 donor screening 
tool. Donor Screening Tool adapted 
from Trillium Gift of Life Network Organ 
Donation Organization, Ontario, Canada
SECTION A:  Institution 
This category describes whether institutional transmission of COVID-19 is of higher risk in the referring hospital. 
Unprotected COVID-19 exposure plus transmission from exposed person to others in donor ICU within the last 14 
days:  yes    no   
SECTION C:  Exposure    
Indicate whether the potential donor has had any of the following:  
    Direct contact with known or suspected COVID-19 case in the last 28 days   yes  no  
    Travel in the last 28 days to high risk region      yes  no  
    Known COVID-19 diagnosis in the last 3 months      yes  no  
High Risk (NO DONATION and No Testing required):
ANY of 
Section A: Yes answer 
Section B: Yes answer 
Moderate to High Risk: Testing required; Do not proceed without testing  
Section C: Yes answer(s) with or without Section D: Yes answer(s) 
Low to Moderate Risk: Testing required; Do not proceed without testing  
Section D:  Yes answer(s), with No answer(s) in Section A, B and C 
Very Low Risk: Testing required; but MAY PROCEED WITH DONATION if test result cannot be obtained in 
time 
No answer(s) in all of Section A, B, C and D
SECTION D:  Clinical 
Indicate whether the potential donor has had the following signs or 
symptoms in the last 28 days, unless another explanation clearly 
exists. 
   fever (> 38oC if taken)    yes  no  
   felt unwell with myalgia and/or headache  yes  no  
   persistent or frequent cough   yes  no  
   shortness of breath    yes  no  
   chest imaging showing lung infiltrates  yes  no  
SECTION B:  Active COVID-19 Infection 
Has the potential donor been identified as a COVID-19 presumptive positive and/or as a COVID-19 confirmed 
case in the last 14 days?     yes    no   
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The decision to pause life-saving transplants such as the liver, 
heart, and lung is more difficult as waitlist mortality is greater. 
However, for liver transplantation patients can be stratified based 
on MELD score and the decision made to only transplant high MELD 
patients. Similarly, transplanting high status patients only may be a 
trade-off to completely stopping deceased donor transplantation.
We suggest a phased approach to decreasing transplant activity 
(Table 2). Such decisions need to be made collectively and depend 
on risk tolerance, hospital capacity and degree of virus activity in the 
jurisdiction. A phased approach can include a 25%, 50%, and 75% 
trigger for activity reduction. Obviously in a situation where health-
care system is completely overwhelmed a 100% reduction may be 
unavoidable.
Another issue to consider is COVID-19 screening of recipients 
(clinical and/or laboratory) being admitted for transplantation. A 
standard screening form could be used. Whether asymptomatic pa-
tients should have a NP swab for COVID-19 NAT is debatable as this 
may be negative during the incubation period and may place unnec-
essary burden on resources. Currently most of the authors’ centers 
(with the exception of South Korea) are not screening asymptomatic 
recipients being admitted for transplantation with NAT.
Outpatient transplant clinics also need to be modified as 
hospitals prepare for increasing numbers of COVID-infected pa-
tients (Table 3). Elective transplant well-visits can be postponed 
and clinics can be scaled back such that only urgent visits need 
to be seen. If resources are available, clinic staff may choose to 
screen all patients by telephone prior to the clinic visit for symp-
toms compatible with COVID-19. Telehealth/telephone calls can 
be substituted for such clinic visits. Transplant programs can direct 
patients to public health websites or transplant-specific websites 
for information.
Manpower issues are equally important. Members of the trans-
plant team should not come to work if experiencing any symptoms 
compatible with COVID-19 and self-isolate if exposure has occurred. 
The authors note that rapid testing of transplant team members with 
even mild symptoms is very important. Transplant teams should 
have clear back-up plans should a team member become ill or quar-
antined. The authors centers have either disallowed vacation or al-
lowed non-travel vacations with the understanding that they may be 
called in to help out—an “all hands on deck” approach.
Although it is difficult to determine the course of the pandemic, 
the majority of hypotheses are based on peak of disease lasting sev-
eral months followed by a stable level with either year-round or sea-
sonal circulation of the virus. At some point transplant programs that 
have decreased activity will need to ramp up. We suggest this could 
be done in a phased approach where more urgent transplants could 
proceed first, with more “elective” cases phased in later. This would 
need to be coupled with safe donation and transplant practices to 
prevent and treat COVID-19, as well as an understanding of local 
health resource limitations.
4  | ROLE OF TR ANSPL ANT INFEC TIOUS 
DISE A SES
An increasing number of programs worldwide have transplant in-
fectious disease (TID) specialists embedded in programs. During 
the COVID-19 pandemic, the TID physician can serve as a critical 
resource in an evolving environment. Although there are no pub-
lications on transplant recipients currently, transplant recipients 
have acquired COVID-19 and anecdotal information suggests that 
there is a spectrum of illness ranging from mild to severe disease. 
It is likely that these patients may also have higher viral loads with 
prolonged shedding. This may require longer quarantine periods 
until patients can be confirmed swab negative (eg, we use 2 con-
secutive negative swabs to terminate quarantine). With regard to 
treatment of an infected transplant recipient, the ID physician can 
be instrumental in obtaining and suggesting experimental thera-
pies. Currently, there are many clinical trials and experimental 
therapies for COVID-19 including remdesivir, lopinavir/ritonavir, 
TA B L E  1   Summary of donor and recipient screening practices
Countrya  Deceased donor screening Living donor screening
Pretransplant recipient 
screening Specimen type
Canadab  Universal NAT Universal NAT Clinical NP or BAL
Switzerland Universal NAT Universal NAT Clinical NP or BAL
Italy Universal NAT Universal NAT Clinical BAL in deceased donor NP 
in living donor
Spain Universal NAT Universal NAT; donation 
postponed 21 d if known 
exposure
Clinical NP ± BAL
Koreab  Universal NAT Universal NAT Universal NAT NP
Japanb  Risk-based NAT due to 
limited testing capacity
Self-isolation or hospital 
admission 14 d prior to surgery
Clinical; NAT where 
testing available
NP (and BAL for intubated 
patients)
Abbreviations: BAL, bronchoalveolar lavage; NAT, nucleic acid testing; NP, nasopharyngeal.
aMay represent the author centers—not necessarily country wide; assumes transplant activity is continuing. 
bRecommendations of country-specific transplant societies. 
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TA B L E  2   Phased approach to new transplant activity during the COVID-19 pandemic
Transplant activity level Priority level description Examples (may include but not limited to)
25% reduction in transplant 
activity
Elective cases. Patients whose 
conditions is deemed nonlife 
threatening or can be managed with 
medication and for whom services 
can be deferred until the end of a 
pandemic wave (ie, 6-8 wk)
• Kidney transplant
a. No living donor activity
b. Deceased donor activity allowed
• Liver transplant
a. No living donor activity for stable recipients
b. Deceased donor activity allowed
• Heart—normal activity
• Lung—normal activity
• Kidney-pancreas/pancreas alone transplant
a. K/P activity allowed







50% reduction in transplant 
activity
Urgent cases. Patients who are 
deemed urgent and who need 
service within 14 d. It may be 
possible to defer these services for a 
few days, but not for the length of a 
pandemic wave.
Physicians will determine that these 
patients are not put at undue risk. If 
their situation changes they will be 
changed to emergent
• Kidney transplant
a. No activity except highly sensitized (eg, PRA of 95% or above with 
suitable donor offer and negative DSA)
• Liver transplant
a. Activity for MELD > 25
b. No living donor activity for stable recipients
• Heart
a. Only intermediate status patients and above
• Lung
a. All patients allowed
b. Defer if patient is stable on waitlist
• Kidney-pancreas transplant
a. No activity except high PRA as above




• No import of organs from select jurisdictions
75% reduction in transplant 
activity
Emergent cases: Patients who are 
deemed critical, whose condition is 
immediately life threatening. Their 
immediate need is greatest
• Kidney transplant
a. No activity unless for medically urgent status (eg, lack of dialysis 
access, uremic cardiomyopathy, uremic neuropathy with paralysis 
and/or respiratory compromise)
• Liver transplant
a. Only fulminant hepatic failure or MELD > 30
• Heart transplant
a. Highest status only (eg, status 3, 3.5, and 4 in Canada)
• Lung transplant
a. Only rapidly deteriorating and status 2 patients (use LAS in US)
• Kidney-pancreas transplant
a. No activity




• No import of organs from select jurisdictions
100% reduction in 
transplant activity
Health system is overwhelmed with 
COVID-19; no ICU or other capacity 
available; severe shortages of health 
personnel
• Halt of all living and deceased donor transplant activity
 Abbreviations: ICU intensive care unit; LAS, lung allocation score; MELD, model for end-stage liver disease; PAK, pancreas after kidney; PRA, panel 
reactive antibody; PTA, pancreas transplant alone.
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darunavir-cobicistat, interferon beta and (hydroxy)chloroquine, 
as well as combinations of these therapies. Passive high-titer im-
munoglobulin from recovered COVID patients has been used. 
Blunting the inflammatory response with a trial of corticosteroids 
is controversial.9,10 However, reduction of IL-6 in critically ill pa-
tients with tocilizumab has also been attempted. Detailed treat-
ment algorithms are beyond the scope of this viewpoint, and are 
continually evolving as new data emerge. Numerous centers and 
groups have developed treatment guidelines for transplant and 
nontransplant patients. Antimicrobial management of the critically 
ill transplant patient (including potential drug interaction between 
antivirals and immunosuppressive drugs), an understanding of ex-
perimental therapies and clinical trials, as well as working with the 
transplant physician in reducing immunosuppression are all roles of 
a transplant infectious disease physician. The TID physician is also 
important at a programmatic level. Since surges in hospital capacity 
are predicted to occur with COVID-19, the TID physician can also 
determine whether non-COVID-19 patients with infections can be 
safely discharged home on oral or home IV therapies. Transplant 
ID physicians can also serve as an educational resource for other 
transplant physicians and coordinators, assist in answering patient 
queries regarding COVID-19. They can also be instrumental in 
building screening strategies for transplant patients, that is decide 
who can be safely managed as outpatient and who needs hospi-
tal admission. Overall, TID physicians can act as a linchpin of the 
transplant program during the COVID-19 pandemic by establishing 
safety procedures of donor and recipients, providing up-to-date 
educational tools, and prioritizing transplant activities according to 
evolution of the epidemiology of the pandemic.
5  | APPROACH TO TR ANSPL ANT 
RESE ARCH AC TIVITIES
An approach needs to be developed for centers that have ongoing 
clinical trials, especially those of novel immunosuppressives, in the 
face of a pandemic. To completely discontinue a trial and withdraw 
patients would generally not be required. However, modifications 
could be made such as halting enrollment of new patients. Patients 
already enrolled in a clinical trial should be advised to practice so-
cial distancing and frequent handwashing. Patients may not wish 
to come to hospital for study visits and this needs to be respected. 
Research teams should liaise with the sponsor for virtual visits. The 
hospital can consider a separate area for study blood work and ad-
ministration or pickup of study drug where study outpatients are 
separated from patients that may be unwell.
In contrast, research for COVID in transplantation is necessary and 
needs to continue. Some areas for research include outcomes in trans-
plant patients, predictive diagnostics, and management strategies in-
cluding optimal approach to immunosuppression adjustment. Vaccines 
are under development and will likely be in clinical trials. When this 
occurs a trial in transplant candidates and recipients is also warranted.
6  | SAFET Y OF THE TR ANSPL ANT TE AM
We must think about steps to take care of ourselves and ensure we 
remain healthy so that we can look after our patients. Risks to think 
about include: (1) teams traveling for donor procurement to areas of 




priority Description (may include but not limited to)
25% reduction in 
transplant activity




• All blood work should be done at outside 
laboratories if possible
• Redeploy Ambulatory Staff to establish 24/7 
call center for patient
50% reduction in 
transplant activity
Should be seen • Recent transplant patients (define for each 
organ)
• Transplant patients with sub-acute/chronic 
complications
• Consider telehealth
75% reduction in 
transplant activity
Need to be seen • Very recent transplants (define for each 
organ)
• Transplant patients with acute complications 









COVID; lack of 
personnel
• Ambulatory activity unable to proceed. 
Referral to community primary care 
physicians if possible
TA B L E  3   Ambulatory transplant 
clinic service reduction during COVID-19 
pandemic
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on deceased donors, and (3) team exposures to transplant recipi-
ents who may be shedding greater quantities of virus (so-called 
super-shedders or super-spreaders). Many of these risks can be miti-
gated by careful use of personal protection measures, and if needed 
avoidance of high-risk situations and following hospital directives 
regarding in-person meetings. Any transplant staff who is ill must im-
mediately excuse themselves from work, and have appropriate test-
ing as needed.
Organization of transplant programs with parallel teams (without 
contact among them) may be appropriate to continue with trans-
plant activity even in case of transmission of cases within health-
care workers. A very important but often neglected issue is the 
mental health of the transplant team. Anxiety and distress related 
to COVID-19 exposure concerns, transplant program closures, and 
adverse outcomes in recipients all may contribute. Closely working 
with the transplant psychiatry team is a proposed strategy for ad-
dressing this.
7  | ROLE OF TR ANSPL ANT SOCIETIES
Transplant societies such as AST, ASTS, TTS, ISHLT, and country-spe-
cific organizations have an important role as an educational resource 
in a rapidly evolving pandemic. Experts within societies should dis-
seminate donor screening algorithms, share advice for transplant 
programs, and management of transplant recipients. The American 
Society of Transplantation has rapidly created an information sheet 
for transplant professionals including suggestions for donor screen-
ing. In addition, information specific for transplant recipients has also 
been created. Similarly, The Transplantation Society has also provided 
information on COVID-19 for transplant professionals. Platforms 
such as webinars, virtual town halls, chat groups can be used to 
quickly exchange information. Transplant societies can also act as 
a conduit for research collaborations on COVID-19. For instance, 
the Spanish Group for the Study of Infection in Transplantation and 
the Immunocompromised Host (GESITRA-IC/SEIMC) has drafted a 
consensus guideline for the therapeutic management of transplant 
recipients with COVID-19 and has established a prospective multi-
center registry to obtain real-time data from clinical experience.
8  | SUMMARY
This is an exceptional time for the world full of uncertainty and anxi-
ety. For those of us working in transplantation, it is especially worri-
some given the highly vulnerable group of patients we serve. In this 
context it is of the utmost importance that we come together as a 
team, to share knowledge and experience that will benefit all of our 
program and most importantly our patients.
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